Cutaneous Melanoma Clinical Trials in Houston, Texas

7 studies are recruiting for cutaneous melanoma in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

   This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   17 in total

   Run by

   Aulos Bioscience, Inc.

   See if you can join NCT05267626 on ClinicalTrials.gov

2. Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

   This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   15 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT03947385 on ClinicalTrials.gov

3. Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma

   This study investigates the extent to which lifestyle factors including mental health, social support, diet, and exercise are associated with quality of life and melanoma patient outcomes. Knowledge gained from this study may be used to guide the design of prospective clinical trials of lifestyle i…

   Stage

   Not phased

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT04778449 on ClinicalTrials.gov

4. ACTengine® IMA203 Combined With mRNA-4203

   This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   4 in total

   Run by

   Immatics US, Inc.

   See if you can join NCT06946225 on ClinicalTrials.gov

5. A Beta-only IL-2 ImmunoTherapY Study

   This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   27 in total

   Run by

   Medicenna Therapeutics, Inc.

   See if you can join NCT05086692 on ClinicalTrials.gov

6. A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

   KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care therapy, cannot tolerate standard of care therapy, r…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   15 in total

   Run by

   Krystal Biotech, Inc.

   See if you can join NCT05970497 on ClinicalTrials.gov

7. A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

   This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oncology Consultants, P.A., Houston, Texas

   Locations

   13 in total

   Run by

   GV20 Therapeutics

   See if you can join NCT05669430 on ClinicalTrials.gov